The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

iwMDS/iwMPN 2026 | Does CAR T-cell therapy have a future in MDS?

Name: Does CAR T-cell therapy have a future in MDS?
Uploaded: 2026-10-03T00:00:00Z
Duration: 12 min 59 s

Mohamed Kharfan Dabaja • 3 Oct 2026

iwMDS/iwMPN 2026

Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes CAR-T

Mohamed Kharfan Dabaja, MD, MBA, FACP, Mayo Clinic, Jacksonville, FL, discusses the potential role of non-transplant cellular therapies in myelodysplastic syndromes (MDS). Dr Kharfan Dabaja highlights emerging CAR T-cell therapies targeting CLL-1 and LILRB4 in myeloid malignancies, exploring challenges related to target selection, immunosuppression, and the potential role of CAR-T as a bridge to allogeneic stem cell transplantation. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.